ArticleJFMS open reports
Sarcoglycanopathy with absent expression of all sarcoglycan proteins in a young cat with clinical features of feline hypertrophic muscular dystrophy.
Article in JFMS open reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Case summary: A 1-year-old, male castrated domestic shorthair cat presented for chronic mobility decline and muscle stiffness, first noted at 3 months of age, and persistently elevated serum creatine kinase levels (>19,000-53,000 IU/l). Clinical examination revealed macroglossia and selective hypertrophy of cervical and appendicular muscles. Neurologic evaluation indicated a myopathic gait without pain or neurologic deficits. Muscle biopsy was supportive of muscular dystrophy (MD) and immunohistochemistry demonstrated loss of the sarcoglycan complex with complete absence of all tested sarcoglycan proteins, consistent with a diagnosis of sarcoglycan-deficient MD. These findings contrast with prior feline reports that were mostly limited to reduction or absence of beta-sarcoglycan on immunostaining without overt clinical evidence of MD. A follow-up echocardiogram revealed mild to moderate right ventricular changes without indications for treatment. At 2 months after diagnosis, the patient remained clinically static, suggesting a relatively slow progression despite absent sarcoglycan expression. Relevance and novel information: This case represents the first reported feline sarcoglycanopathy characterized by the absence of all tested sarcoglycan subunits on immunohistochemistry and concurrent presentation of classic Duchenne-like MD signs, including macroglossia and muscular hypertrophy. It expands the phenotypic spectrum of muscular dystrophies in cats, underscoring parallels to limb-girdle muscular dystrophies in humans and dogs. Given the cat's static clinical course and diagnostic overlap with dystrophinopathies, this case suggests sarcoglycan-deficient MD in cats may present with a broader spectrum of severity than previously appreciated. The findings support the potential utility of feline sarcoglycanopathies, when phenotypically consistent with forms appreciated in other species, as spontaneous animal models for comparative medical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.